Adjuvant therapies in advanced hepatocellular carcinoma: Moving forward from the STORM

Abstract

Like other previous treatments and approaches, sorafenib, an antiangiogenic drug, failed to show any benefit in the adjuvant setting for hepatocellular carcinoma in a large clinical trial. We discuss reasons and implications of these negative results and the implications for clinical practice and future research. Trial registration: ClinicalTrials.gov: NCT00692770. Registered 5 June 2008. This study has been completed.